Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares hit a new 52-week low during trading on Monday . The stock traded as low as $0.22 and last traded at $0.26, with a volume of 2230800 shares traded. The stock had previously closed at $0.28.
Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $1.50 target price (down from $4.50) on shares of Bio-Path in a report on Monday, November 13th. reduced their target price on Bio-Path from $4.50 to $1.50 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Finally, ValuEngine downgraded Bio-Path from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Bio-Path presently has a consensus rating of “Hold” and a consensus target price of $1.67.
Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, November 9th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). research analysts forecast that Bio-Path Holdings, Inc. will post -0.08 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Bio-Path (BPTH) Sets New 52-Week Low at $0.22” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/04/bio-path-bpth-sets-new-52-week-low-at-0-22.html.
Bio-Path Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
What are top analysts saying about Bio-Path Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Path Holdings Inc. and related companies.